Method for preparing nanoparticles and method for preparing nano drug-carrying particles
By chemically combining polyglutamic acid and tannin acid into nanoparticles, the problem of lack of this composite technology in the prior art is solved, and the preparation of nanomedicine-loaded particles is realized, with excellent performance and good biocompatibility, suitable for It is used for loading water-soluble antibiotic drugs, which significantly improves the therapeutic effect.
Patent Information
- Application Number
- CN202310333716.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-31
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-03-31
AI Technical Summary
There is no technical solution in the prior art to chemically compound polyglutamic acid and tannin acid into nanoparticles and apply it to drug-carrying drugs, which limits its development and application in the field of biomedicine.
By obtaining the first solution (including polyglutamic acid, tannic acid, water and N,N-dimethylformamide) and the second solution (including carboxy catalyst and water), and adding the second solution to the first solution After the reaction, solid-liquid separation was performed to prepare spherical nanoparticles with a particle size of 80-200 nm, and further combine them with the drug on the basis of them to prepare nanomedicine-carrying particles.
It realizes nanoparticles and nanomedicine-loading particles with simple and controllable processes and excellent performance. It can payload water-soluble antibiotic drugs with benzene rings and positive electrostatic groups, has good biocompatibility and the ability to slowly release drugs, reducing Toxic side effects to improve the therapeutic effect.
Smart Images

Figure CN116327708B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nano drug delivery technology, and in particular to a method for preparing nanoparticles and a method for preparing nano drug-loaded particles. Background Art
[0002] The development of nano-drug delivery technology is of great significance, as it may significantly improve the efficacy of existing drugs and allow the development of new drugs that cannot be achieved by traditional drug delivery methods. In recent years, research on nano-drug delivery systems in the treatment of a variety of diseases such as cancer, cardiovascular disease and infectious diseases has grown rapidly. By encapsulating drugs in small nano-sized particles, there are many advantages: the solubility and stability of the drugs are improved, thereby enhancing the efficacy and reducing side effects; the drugs can be delivered to specific cells or tissues in a targeted manner, reducing systemic side effects; the release of drugs can be controlled, thereby reducing the frequency of medication and improving patient compliance. By reducing systemic side effects, the quality of life of patients receiving treatment can be improved. Targeted delivery of drugs to specific cells or tissues can greatly improve the efficiency of treatment, reduce the amount of drug used and minimize the risk of systemic toxicity.
[0003] The application of polyglutamic acid derivatives and their composite materials in the biomedical field has attracted wide attention. Polyglutamic acid-based composite materials have been developed into antibacterial compounds, drug carriers and cancer treatment materials, and are also used in medical devices and inflammation regeneration. Tannic acid is a common polyphenol substance with antioxidant, anti-inflammatory, anti-tumor and antimicrobial effects. Its multiple biological activities have led to its extensive research in the fields of biomedicine and the like. However, there is no technical solution in the prior art to chemically compound polyglutamic acid and tannic acid into nanoparticles and apply them to drug delivery. Summary of the invention
[0004] The main purpose of the present invention is to provide a method for preparing nanoparticles and a method for preparing nano drug-loaded particles, which have simple and controllable processes and can compound polyglutamic acid and tannic acid into nanoparticles.
[0005] In order to achieve the above object, the present invention first provides a method for preparing drug-carrying nanoparticles, and the technical scheme is as follows:
[0006] The preparation method of drug-carrying nanoparticles comprises the following steps: obtaining a first solution, wherein the first solution comprises polyglutamic acid, tannic acid, water and N,N-dimethylformamide; obtaining a second solution, wherein the second solution comprises a carboxyl catalyst and water; adding the second solution to the first solution, reacting for a period of time to generate a solid-liquid mixture, and then subjecting the mixture to solid-liquid separation treatment to obtain nanoparticles.
[0007] As a further improvement of the above preparation method: the particle size of the nanoparticles is 80-200 nm, and the nanoparticles are spherical.
[0008] As a further improvement of the above preparation method: the preparation of the first solution includes the steps of: firstly dissolving polyglutamic acid and tannic acid in water; then adding N,N-dimethylformamide and stirring at 3-5°C for 20-40 minutes to obtain the first solution.
[0009] As a further improvement of the above preparation method: in the first solution, the volume ratio of water to N,N-dimethylformamide is (5-7):1.
[0010] As a further improvement of the above preparation method: the polyglutamic acid is γ-polyglutamic acid; the carboxyl catalyst is 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride.
[0011] As a further improvement of the above preparation method: the mass ratio of γ-polyglutamic acid, tannic acid and 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride is 1:(0.2~0.3):(0.75~1.25); the volume ratio of the first solution and the second solution is (8~12):1.
[0012] As a further improvement of the above preparation method: the second solution is added dropwise to the first solution at a rate of 0.05 to 0.05 mL / s, and the reaction is carried out for 6 to 10 hours after the addition is completed.
[0013] In order to achieve the above object, the present invention provides two methods for preparing nano drug-carrying particles, and the technical scheme is as follows:
[0014] The first method for preparing nano drug-carrying particles comprises the following steps: obtaining the nano particles prepared by the above-mentioned preparation method; dispersing the nano particles and the drug in water to obtain a dispersion containing the nano drug-carrying particles. Preferably, the drug is a water-soluble antibiotic drug with a benzene ring and a positively charged group.
[0015] The second method for preparing nano drug-loaded particles comprises the following steps: adding a drug to the first solution or the second solution in the above-mentioned preparation method; and in situ loading the drug on the nanoparticles during the generation of the nanoparticles, thereby obtaining nano drug-loaded particles. Preferably, the drug is a water-soluble antibiotic drug with a benzene ring and a positively charged group.
[0016] The preparation method of the present invention and the prepared nanoparticles and nano-drug-loaded particles have the following advantages:
[0017] (1) The process is simple and controllable. Compared with physically combined polyglutamic acid and tannic acid, the chemically composited nanoparticles have better performance.
[0018] (2) The obtained particles are nanometer-sized and have a large specific surface area, which can significantly increase the drug loading capacity.
[0019] (3) It has been verified that the nanoparticles are negatively charged and have benzene rings, which enables a variety of drug delivery methods and is particularly suitable for loading water-soluble antibiotic drugs with benzene rings and positively charged groups.
[0020] (4) Nano drug-loaded particles can participate in the human body's blood circulation and normal metabolism.
[0021] (5) Nano drug-loaded particles can achieve slow release of drugs, reduce toxic side effects, and help improve therapeutic effects.
[0022] (6) All raw materials used are natural compounds and have no toxic side effects on the human body.
[0023] (7) Nanoparticles and nanodrug-loaded particles are non-toxic and have good biocompatibility.
[0024] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments. Additional aspects and advantages of the present invention will be partially given in the following description, partially become apparent from the following description, or be learned through the practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] The drawings constituting a part of the present invention are used to assist in understanding the present invention. The contents provided in the drawings and their related descriptions in the present invention can be used to explain the present invention, but do not constitute improper limitations on the present invention. In the drawings:
[0026] Figure 1 SEM photos of nanoparticles.
[0027] Figure 2 Zeta potential distribution diagram of nanoparticles.
[0028] Figure 3 The UV absorption curves of nanoparticles, γ-PGA and TA.
[0029] Figure 4 Drug release curves of DLNPs and FreeDCH.
[0030] Figure 5 Schematic diagram of the in vitro cytotoxicity test results of nanoparticles at different concentrations. DETAILED DESCRIPTION
[0031] The present invention is described clearly and completely below in conjunction with the accompanying drawings. A person skilled in the art will be able to implement the present invention based on these descriptions. Before describing the present invention in conjunction with the accompanying drawings, it should be particularly noted that:
[0032] The technical solutions and technical features provided in each part of the present invention, including the following description, may be combined with each other if there is no conflict.
[0033] In addition, the embodiments of the present invention involved in the following description are generally only a part of the embodiments of the present invention, rather than all the embodiments. Therefore, based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.
[0034] About the terms and units in the present invention: The terms "include", "have" and any variations thereof in the description and claims of the present invention and related parts are intended to cover non-exclusive inclusions.
[0035] The specific implementation of the method for preparing drug-loaded nanoparticles of the present invention comprises the following steps:
[0036] (1) obtaining a first solution, wherein the first solution comprises polyglutamic acid (PGA), tannic acid (TA), water and N,N-dimethylformamide (DMF);
[0037] Specifically, PGA and TA were first dissolved in water, and then DMF was added and stirred at 4° C. for 30 min to obtain a first solution.
[0038] Since the phenolic hydroxyl groups on the outside of TA are hydrophilic and the internal ring structure is hydrophobic, it dissolves slowly in aqueous solution. Therefore, DMF is used as an auxiliary solvent in the system, which is both miscible with water and can assist in the dissolution of TA. When the volume ratio of water to N,N-dimethylformamide is (5-7):1, the first solution with the best dissolution effect can be obtained.
[0039] Preferably, the PGA is γ-polyglutamic acid (γ-PGA). γ-PGA, as a polymer of amino acids, has good biocompatibility.
[0040] (2) obtaining a second solution, wherein the second solution comprises a carboxyl catalyst and water;
[0041] The carboxyl catalyst is 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (DMTMM), and DMTMM can effectively activate the carboxyl group, thereby promoting the reaction between the carboxyl group of γ-PGA and TA.
[0042] When the mass ratio of γ-PGA, TA and DMTMM is 1:(0.2-0.3):(0.75-1.25) and the volume ratio of the first solution to the second solution is (8-12):1, the catalytic reaction is sufficient and the particle size distribution of the obtained nanoparticles is uniform.
[0043] (3) adding the second solution to the first solution, reacting for a period of time to generate a solid-liquid mixture, and then subjecting the mixture to solid-liquid separation to obtain nanoparticles;
[0044] Preferably, the second solution is added dropwise to the first solution at a rate of 0.067 mL / s and the reaction is continued for 8 hours after the addition is completed, so that the reaction can be more thorough.
[0045] An optimal process parameter is: the first solution consists of 0.2 g γ-PGA, 0.05 g TA, 17 mL water and 3 mL DMF, and the second solution consists of 0.2 g DMTMM and 2 mL water, that is, the mass ratio of γ-PGA, TA and DMTMM is 1:0.25:1, the volume ratio of water and N,N-dimethylformamide is 5.67:1, and the volume ratio of the first solution to the second solution is 10:1.
[0046] Figure 1 SEM photos of nanoparticles.
[0047] from Figure 1 It can be seen that the nanoparticles are spherical and the diameter of the particles is 80 to 200 nm.
[0048] Figure 2 Zeta potential distribution diagram of the obtained nanoparticles.
[0049] like Figure 2 As shown, the nanoparticle potential is -57.3±0.95 mV.
[0050] Figure 3 The UV absorption curves of nanoparticles, γ-PGA and TA.
[0051] from Figure 3 It can be seen that γ-PGA has the strongest absorption peak at 290nm, and TA has the strongest absorption peak at 325nm. After the two raw materials are synthesized into nanoparticles, since γ-PGA is the main component of the nanoparticles, the strongest absorption peak of the nanoparticles is at 315nm, which is between the absorption peaks of the two raw materials. This shows that the particles contain polyglutamic acid and tannic acid, proving that polyglutamic acid and tannic acid are successfully chemically compounded.
[0052] The first embodiment of the method for preparing the nano drug-carrying particles of the present invention comprises the following steps: dispersing the nano particles prepared by the above preparation method and the drug in water to obtain a dispersion containing the nano drug-carrying particles. The dispersion is then subjected to solid-liquid separation to obtain the nano drug-carrying particles.
[0053] The second embodiment of the method for preparing nano drug-loaded particles of the present invention is: based on the above-mentioned method for preparing nano particles, drugs are added to the first solution or the second solution, and the other steps remain unchanged, so that the drugs can be loaded on the nano particles in situ during the generation process of the nano particles, and nano drug-loaded particles can be obtained.
[0054] Compared with the first embodiment, the binding force between the drug and the nanoparticles in the nano drug-loaded particles of the second embodiment is stronger, which can significantly improve the targeted drug release effect and the sustained release effect.
[0055] In the above two embodiments, the added mass of the drug should be ≤ the mass of TA, otherwise it will cause drug waste. Preferably, the mass ratio of TA to drug is (1.5-2):1, at which time the mass fraction of the drug in the nano drug-loaded particles can reach 30%, achieving a high drug loading.
[0056] The drug is preferably selected to have a certain water solubility and have electrostatic adsorption and III stacking effects. Since the Zeta potential of the nanoparticles is -57.3±0.95mV and has a benzene ring, the drug is preferably a water-soluble antibiotic drug with a benzene ring and a positively charged group, such as but not limited to doxycycline hydrochloride (DCH).
[0057] The following is the drug release test result of the nano drug-loaded particles of the second embodiment.
[0058] The experimental method is as follows: prepare two centrifuge tubes with a volume of 80 mL and add 60 mL PBS to the centrifuge tubes. 1 mL of the dispersion of drug-loaded nanoparticles (labeled as DLNPs) and 1 mL of DCH solution (labeled as FreeDCH) are respectively loaded into dialysis bags (MWCO = 5000 Da). FreeDCH and DLNPs contain equal amounts of doxycycline hydrochloride. The two dialysis bags are immersed in two centrifuge tubes respectively and placed in a constant temperature shaker (37 ° C, 100 rpm) for incubation. Take 600 μL of solution each time at the preset time point, and then add 600 μL of clean PBS. The content of doxycycline hydrochloride in the taken solution is tested by ultraviolet spectrophotometer, and finally the drug release of DLNPs and FreeDCH is compared by statistically analyzing the cumulative release rate of doxycycline hydrochloride.
[0059] Figure 4 Drug release curves of DLNPs and FreeDCH.
[0060] like Figure 4 As shown, the drug release rate of DLNPs is significantly lower than that of FreeDCH, indicating that the nano drug-loaded particles of the present invention can significantly improve the therapeutic effect.
[0061] The following are the results of in vitro cytotoxicity tests of the nanoparticles.
[0062] The in vitro cytotoxicity test of the nanoparticles was carried out using the MTT colorimetric method to evaluate the toxicity of the nanoparticles to mouse fibroblasts (L929), specifically:
[0063] L929 cells were cultured at a density of 2×10 3 / well was inoculated into a 96-well plate, and after incubation for 16 hours, the cells adhered to the wall and grew to a plate density of nearly 50-60%, and then 100 μL DMEM medium and different concentrations (5, 20, 80 μg / mL) of nanoparticle dispersion were added to each well for co-culture with L929 cells. A blank control was set up, that is, the same volume of physiological saline was used instead of the nanoparticle dispersion. Among them, DMEM medium is a modified medium mixed with penicillin / streptomycin antibiotics and fetal bovine serum (mass fraction 10%).
[0064] The survival and proliferation of cells were observed on the 1st, 4th and 7th days after co-culture. After the culture, the cells were slowly washed along the well wall with PBS buffer, and 200 μL DMEM medium and 20 μL (5.0 mg / mL) MTT were added to each well. The well plate was placed in a cell culture incubator and incubated for 4 hours. After the culture was completed, the well medium was removed, and 100 μL dimethyl sulfoxide was added and mixed evenly. The absorbance value of the well plate solution at 570 nm was measured using an ELISA instrument, and the cell survival and proliferation images were drawn based on the absorbance value.
[0065] Figure 5 Schematic diagram of the in vitro cytotoxicity test results of nanoparticles at different concentrations.
[0066] like Figure 5 As shown, in the cell survival rate test on days 1, 4, and 7, there was no significant difference between the experimental groups with different concentrations and the blank control group, no cytotoxicity, and the cell proliferation of each experimental group was similar to that of the blank control group, and even at a high concentration of 80 μg / mL, there was no significant effect on cell proliferation. It can be seen that the nanoparticles composited with polyglutamic acid and tannic acid of the present invention have good cell compatibility.
[0067] The above is a description of the relevant contents of the present invention. A person skilled in the art will be able to implement the present invention based on these descriptions. Based on the above contents of the present invention, all other embodiments obtained by a person skilled in the art without creative work shall fall within the scope of protection of the present invention.
Claims
1. A method for preparing drug-carrying nanoparticles, characterized in that: The following steps are involved: obtaining a first solution, wherein the first solution comprises polyglutamic acid, tannic acid, water and N,N-dimethylformamide; obtaining a second solution, wherein the second solution comprises a carboxyl catalyst and water; Adding the second solution to the first solution, reacting for a period of time to generate a solid-liquid mixture, and then subjecting the mixture to solid-liquid separation to obtain nanoparticles; The polyglutamic acid is γ-polyglutamic acid; the carboxyl catalyst is 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride.
2. The preparation method according to claim 1, characterized in that: The particle size of the nanoparticles is 80 to 200 nm, and the nanoparticles are spherical.
3. The preparation method according to claim 1, characterized in that: The preparation of the first solution comprises the following steps: firstly dissolving polyglutamic acid and tannic acid in water; then adding N,N-dimethylformamide and stirring at 3-5°C for 20-40 minutes to obtain the first solution.
4. The preparation method according to claim 1, characterized in that: In the first solution, the volume ratio of water to N,N-dimethylformamide is (5-7):
1.
5. The preparation method according to claim 1, characterized in that: The mass ratio of γ-polyglutamic acid, tannic acid and 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride is 1:(0.2-0.3):(0.75-1.25); the volume ratio of the first solution to the second solution is (8-12):
1.
6. The preparation method according to claim 1, characterized in that: The second solution is added dropwise to the first solution at a rate of 0.05 to 0.05 mL / s, and the reaction is carried out for 6 to 10 hours after the addition is completed.
7. A method for preparing nano drug-loaded particles, characterized in that: The following steps are involved: Obtain nanoparticles prepared by the preparation method according to any one of claims 1 to 6; The nanoparticles and drugs are dispersed in water to obtain a dispersion containing nano drug-carrying particles.
8. A method for preparing nano drug-loaded particles, characterized in that: The following steps are involved: The preparation method according to any one of claims 1 to 6, wherein a drug is added to the first solution or the second solution; During the process of generating nanoparticles, the drug is loaded on the nanoparticles in situ, thus obtaining drug-loaded nanoparticles.
9. The preparation method according to claim 7 or 8, characterized in that: The drug is a water-soluble antibiotic drug with a benzene ring and a positively charged group.
